BridgeBio Pharma presented the interim analysis of its Phase 3 FORTIFY trial for the oral small‑molecule BBP‑418 at the MDA Clinical and Scientific Conference on March 11, 2026. The data showed consistent efficacy across key clinical endpoints and early separation from placebo on the 100‑meter timed test (100MTT) as soon as three months after treatment initiation.
The 12‑month results revealed that BBP‑418‑treated participants completed the 100MTT approximately 31 seconds faster than placebo recipients, while the 10‑meter walk test (10MWT) improvement was 0.13 m/s versus a 0.10 m/s decline in the placebo arm. Serum creatine kinase (CK) levels fell markedly, with 59.6 % of patients achieving values within twice the upper limit of normal and 38.3 % reaching normalization after 12 months.
Safety data were favorable, with no new safety signals reported and a tolerability profile comparable to placebo. The early functional gains and biomarker improvements suggest a rapid onset of action for BBP‑418 in this progressive muscle disease.
BridgeBio plans to file a New Drug Application with the U.S. Food and Drug Administration in the first half of 2026, with a U.S. launch anticipated in late 2026 or early 2027 if approval is obtained. The presentation also highlighted the potential for expedited approval pathways in Europe and the company’s intention to initiate studies in younger patients with similar conditions.
The results position BBP‑418 as the first approved therapy for individuals with limb‑girdle muscular dystrophy type 2I/R9, addressing a significant unmet medical need. Analysts project peak sales of at least $600 million, and the company’s management emphasized the rapid onset of action and the commitment to move swiftly toward approval. Dr. Katherine Mathews noted, "People living with LGMD2I/R9 face a real unmet medical need. There is currently no specific treatment, the disease often has an early age of onset, and it is relentlessly progressive, leading to irreversible loss of motor function. The early separation from placebo on 100MTT is especially encouraging. In a progressive muscle disease where time matters, seeing early improvements in ambulation suggests a rapid onset of action of BBP‑418." Douglas Sproule added, "The FORTIFY results reaffirm the power of targeting this genetic disease at its source with relentless focus and compassion. For individuals living with LGMD2I/R9, a condition that slowly takes away the strength, breathing, and independence of an individual, each day matters. We are determined to move swiftly toward filing for approval, so that BBP‑418, if approved, can become the first therapy to change the course of this devastating disease."
The announcement was well received by investors, reflecting confidence in the drug’s potential and the company’s strategy to bring a first‑in‑class therapy to a rare disease market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.